EUVIMEDEUVIMED entdecken
Crossref

PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway

Hu-Ying Tang, Jia-Qi Guo, Bo-Tao Sang, Jun-Ning Cheng, Xiang-Mei Wu

Biochemistry and Cell Biology · 2022-02 · 100 (1) · 75-84

DOI: 10.1139/bcb-2021-0305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemistry and Cell Biology, 2022-02. Verfasst von Hu-Ying Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Basic Medical College, Chongqing Medical University, Chongqing 400016, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Osteosarcoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma is a malignant tumor abundant in vascular tissue, and its rich blood supply may have a significant impact on its metabolic characteristics. PDGFRβ is a membrane receptor highly expressed in osteosarcoma cells and vascular wall cells, and its effect on osteosarcoma metabolism needs to be further studied. In this study, we discussed the effect and mechanism of action of PDGFRβ on glucose metabolism in human osteosarcoma (HOS) cells. GSEA, Pearson’s correlation test, and PPI correlation analysis indicated positive regulation of PDGFRβ on aerobic glycolysis in osteosarcoma. The results of qPCR and western blot further confirmed the prediction of bioinformatics. Glucose metabolism experiments proved that PDGF/PDGFRβ could effectively promote aerobic glycolysis in osteosarcoma cells. In addition, the mitochondrial membrane potential (ΔΨm) experiment proved that the metabolic change triggered by PDGFRβ was not caused by mitochondrial damage. The PI3K pathway inhibitor LY294002, MEK pathway inhibitor U0126, or Warburg effect inhibitor DCA was used to perform western blot and glucose metabolism experiments, and the results showed that PDGFBB/PDGFRβ mainly activated the PI3K/AKT/mTOR/c-Myc pathway to promote aerobic glycolysis in osteosarcoma HOS cells. The newly elucidated role of PDGFRβ provides a novel metabolic therapeutic target for osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsOsteosarcomaCell Line, TumorCell ProliferationGlucoseGlycolysisHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Platelet-Derived Growth Factor betaTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

PDGFRβaerobic glycolysisc-Mycglycolyse aérobiemetabolic reprogrammingosteosarcomaostéosarcomereprogrammation métabolique

Substanzen

GlucosePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Platelet-Derived Growth Factor betaTOR Serine-Threonine KinasesMTOR protein, humanPDGFRB protein, human

Autor:innen und Institutionen

  • Department of Physiology, Basic Medical College, Chongqing Medical University, Chongqing 400016, China.
  • Molecular Medicine and Cancer Research Center, Basic Medical College, Chongqing Medical University, Chongqing 400016, China.
  • Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Zitieren

APA

Tang, H. Y., Guo, J. Q., Sang, B. T., Cheng, J. N., & Wu, X. M. (2022). PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway. Biochemistry and Cell Biology, 100(1), 75-84. https://doi.org/10.1139/bcb-2021-0305

Vancouver

Tang HY, Guo JQ, Sang BT, Cheng JN, Wu XM. PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway. Biochemistry and Cell Biology. 2022;100(1):75-84. doi:10.1139/bcb-2021-0305

BibTeX
@article{Tang2022,
  author = {Tang, Hu-Ying and Guo, Jia-Qi and Sang, Bo-Tao and Cheng, Jun-Ning and Wu, Xiang-Mei},
  title = {PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway},
  journal = {Biochemistry and Cell Biology},
  year = {2022},
  volume = {100},
  number = {1},
  pages = {75--84},
  doi = {10.1139/bcb-2021-0305}
}
Kostenlos starten →